Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009

CRANBURY, N.J., Feb. 11 Palatin Technologies, Inc. (NYSE Alternext US: PTN) will announce its second quarter, fiscal year 2009 financial results on Tuesday, February 17, 2009 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 17, 2009, which will include discussion of the results of operations in greater detail and an update on corporate developments.

Schedule for the Financial Results Press Release, Conference Call and Webcast

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

- Q2-Fiscal Year 2009 Financial Results Press Release 2/17/2009 at 7:30 a.m. ET - Q2-Fiscal Year 2009 Conference Call - Live 2/17/2009 at 11:00 a.m. ET Domestic Dial-In Number 1- 888-631-5927 International Dial-In Number 1- 913-312-0661 Passcode: 5142197 - Q2-Fiscal Year 2009 Conference Call - Replay 2/17-2/24/2009 Domestic Dial-In Number 1- 888-203-1112 International Dial-In Number 1- 719-457-0820 Replay Passcode: 5142197 - Webcast Live and Replay Access http://www.palatin.com The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com.

SOURCE Palatin Technologies, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...